Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,310 matching trials from the live ClinicalTrials.gov search.
Conditions
Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation, SPG50, Spastic Paraplegia
Interventions
MELPIDA
Biological
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
4 Months to 10 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Results available

Effect of Weight Loss on Prostate Cancer Pathology

NCT00475982
Conditions
Obesity, Prostate Cancer
Interventions
Weight Loss, No Weight Loss Group
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
West Los Angeles, California
Conditions
Burn, Growth, Malnutrition
Interventions
Calcium,Vitamin D, Calcium, VitaminD, Sugar Pill
Dietary Supplement · Other
Lead sponsor
Kathy Prelack, PhD, RD
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
Interventions
Tivozanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 2 Interventional Results available

Malignant Pleural Effusion With ZD6474

NCT00402896
Conditions
Lung Cancer, Pleural Effusion
Interventions
ZD6474
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

NCT01860339
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
Peggy C Nopoulos
Other
Eligibility
6 Years to 30 Years
Enrollment
488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2026
U.S. locations
6
States / cities
Sacramento, California • Iowa City, Iowa • New York, New York + 3 more
Conditions
Non-small Cell Lung Cancer
Interventions
Ramucirumab, Necitumumab, Osimertinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Craniofacial Abnormalities
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
1 Year to 80 Years
Enrollment
1,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions
VEGF Trap-Eye 2.0mg, Sham
Biological · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
Conditions
Metastatic Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

NCT02553330
Conditions
Alopecia Areata
Interventions
Placebo Cream, Ruxolitinib Phosphate Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • New Haven, Connecticut + 15 more
Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions
Ipilimumab, Osimertinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
HER2-positive Breast Cancer
Interventions
HER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Intermittent Claudication, Arteriosclerosis
Interventions
DNA Plasmid Vector, EW-A-401 DNA Plasmid Vector
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Bethesda, Maryland • Madison, Wisconsin
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly

NCT01410799
Conditions
Hormone Deficiency, Aging
Interventions
Growth Hormone Releasing Hormone (GHRH )
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lung Cancer, Breast Cancer
Interventions
BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
14
States / cities
Birmingham, Alabama • Miami, Florida • Iowa City, Iowa + 9 more
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
Conditions
Ovarian Neoplasms
Interventions
AMG 479, AMG 479 Placebo
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
23
States / cities
Alhambra, California • Burbank, California • Fullerton, California + 17 more
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Completed No phase listed Observational Results available

Predicting Placental Pathologies by Ultrasound Imaging

NCT04506970
Conditions
Intrauterine Growth Restriction, Villitis, IUGR
Interventions
Comprehensive Doppler Ultrasound of the Placenta, Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Terminated No phase listed Observational Accepts healthy volunteers

Endocrine and Psychological Evaluation of Adopted Children

NCT00368043
Conditions
Psychosocial Adjustment
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Months to 4 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Renal Cell Carcinoma
Interventions
Belzutifan, Zanzalintinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
San Francisco, California • Mineola, New York • New York, New York + 3 more
Conditions
Diabetic Macular Edema, Cataract
Interventions
Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Atlanta, Georgia